1 / 15

Treatment of hypertension in patients with peptic ulcer and liver pathology

Treatment of hypertension in patients with peptic ulcer and liver pathology. DM Leonid Lazebnik DM Olga Mikheeva The Central Research institute of gastroenterology Russian Federation, Moscow 2010. Urgency of the problem.

aira
Download Presentation

Treatment of hypertension in patients with peptic ulcer and liver pathology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Treatment of hypertension in patients with peptic ulcer and liver pathology DM Leonid Lazebnik DM Olga Mikheeva The Central Research institute of gastroenterology Russian Federation, Moscow 2010

  2. Urgency of the problem Statistics show that the increase in blood pressure is observed in 40% of the population, of which 30% of patients with hypertension combined with the pathology of the liver For correction of BP are used antihypertensive drugs of various groups, among which most often appointed are ACE inhibitors

  3. Pharmacokinetic classification of ACE inhibitors Pharmacologically active drugs (captopril), which are metabolized and converted into active disulfides Inactive prodrugs converted in the liver to active metabolites (enalapril to enalaprilat), which are then metabolized into inactive compounds Water-soluble drugs (lisinopril), which are not subjected to metabolism and eliminated through the kidneys unchanged

  4. Purpose of the study To investigate the pharmacokinetic and pharmacodynamic characteristics of lisinopril in the treatment of patients with arterial hypertension, occurring on the background pathology of the digestive system

  5. Studydesign • The control group consisted of patients with peptic ulcer disease without dysfunction of the liver

  6. Indicators of ABPM in the treatment lisinopril 10 mg hypertensive patients with pathology of the digestive According to the ABPM all examined patients initially had increased BP No significant differences among indicators ABPM hypertensive patients with different pathologies of the digestive system have been identified

  7. Indicators of ABPM in hypertensive patients with pathology of the digestive system during treatment with lisinopril 10 mg averagedailyDBP averagedaily SBP мм Hg мм Hg averagedailyITDBP averagedailyITSBP % % Treatment with lisinopril 10 mg leads to significantly decreased mean BP values, temporary index (IT)BPin most patients, regardless of the severity of liver changes in patients with hypertension

  8. The effectiveness (ITBP< 30 %) of monotherapy with lisinopril in hypertensive patients with pathology of the digestive system

  9. The effectiveness of monotherapy with lisinopril in hypertensive patients with pathology of the liver We got a good hypotensive effect in the treatment with lisinopril 10 mg in 53.3% of the patients with cirrhosis. Increasing the dose in half, gave a good effect even in 33,3% of patients In 53,3% of patients with hypertension of the control group a good hypotensive effect was achieved when taking 10 mg, 30% of patients - 20 mg of lisinopril per day

  10. Pharmacokineticstudy • We studied the pharmacokinetics after a single dose of lisinopril 10 mg in patients with hypertension and gastrointestinal disorders • We determined the concentration of lisinopril in serum of patients by high performance liquid chromatography

  11. Themainpharmacokineticparameters The area under the curve "concentration - time" (AUC) - an area the figure bounded pharmacokinetic curve and the coordinate axes C max - maximum concentration of drug in serum (ng/ml) T max - time of maximum concentration of drugs (t) MRT - mean residence time of drugs(t)

  12. Pharmacokinetic parameters of lisinopril 10 mg in hypertensive patients with digestive diseases ngt/ml ngt/ml t t We found that in patients in both groups were observed no differences in pharmacokinetic parameters after taken of 10 mg of lisinopril

  13. Pharmacokinetic and pharmacodynamic curves for hypertensive patients with pathology of the digestive system while taking 10 mg of lisinopril concentration of lisinopril Ng/ml t mean BP, mmHg Pharmacokinetic parameters did not differ in hypertensive patients depending on the pathology of the gastrointestinal tract t

  14. Water-soluble lisinopril is not subjected to metabolism of the patient, therefore, its concentration in plasma is determined the dose taken inside Differences of each pharmacokinetic parameter (C max, T max, MRT, AUC) in groups of BP patients with various pathologies of the digestive sistem were statistically insignificant Pharmacokinetic parameters of lisinopril 10 mg in hypertensive patients with hepatic pathology

  15. Conclusion Water-soluble lisinopril initially pharmacologically active form, therefore has an advantage over ACE inhibitors, which are metabolized in the liver We observed no differences in pharmacokinetic parameters in patients with BP, both normal and with impaired liver function after taking lisinopril 10 mg This is expressed in reaching target BP levels in 53,3% of patients in both groups

More Related